Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome

Endokrine und zielgerichtete Therapie des metastasierten Mammakarzinoms
Endokrine Therapie des metastasierten Mammakarzinoms

- **Versionen 2002–2019:**
  Albert / Bischoff / Dall / Fasching / Fersis / Friedrich / Gerber / Huober / Janni / Jonat / Kaufmann / Kolberg-Liedtke / Loibl / Lüftner / Lück / von Minckwitz / Möbus / Müller / Mundhenke / Nitz / Schmidt / Schneeweiß / Schütz / Stickeler / Thill

- **Version 2020:**
  Thill / Untch


Meta-analysis:

Additional literature:


Endokrine Therapie der prämenopausalen Patientin mit HER2-negativem metastasiertem Mammakarzinom

<table>
<thead>
<tr>
<th>Therapie</th>
<th>LoE</th>
<th>GR</th>
<th>AGO</th>
</tr>
</thead>
<tbody>
<tr>
<td>GnRH-A + Fulvestrant + Palbociclib</td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>GnRH-A + AI + Palbociclib</td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>GnRH-A + AI + Ribociclib</td>
<td>1b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>GnRH-A + Fulvestrant + Abemaciclib</td>
<td>2b</td>
<td>B</td>
<td>++</td>
</tr>
<tr>
<td>GnRH-A + Tamoxifen (vs. OFS od. Tam)</td>
<td>1a</td>
<td>A</td>
<td>++</td>
</tr>
<tr>
<td>Unterdrückung der Ovarialfunktion (OFS)</td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td>GnRH-A + AI (first + second line)</td>
<td>2b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td>GnRH-A + Fulvestrant</td>
<td>1b</td>
<td>B</td>
<td>+</td>
</tr>
<tr>
<td>Aromataseinhibitoren ohne OFS</td>
<td>3</td>
<td>D</td>
<td>-</td>
</tr>
</tbody>
</table>

* Extrapoliert aus Daten postmenopausaler Patientinnen (mit AI)

GnRHa plus fulvestrant plus palbociclib

GnRHa plus AI plus palbociclib
1. Layman RM et al. Comparative effectiveness of palbociclib plus letrozole vs. letrozole for metastatic breast cancer in US-real world clinical practises, ESMO 2019, #329P

GnRHa plus AI/Tamoxifen plus ribociclib
1. Tripathy D et al. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. SABCS 2017, GS-2

GnRH plus Fulvestrant + Abemaciclib

GnRHa plus tamoxifen (vs. OFS or tam)

Ovarian function suppression (OFS), tamoxifen

GnRHa plus AI (first or second line)


GnRHa plus fulvestrant


Fulvestrant 500 mg (vs. anastrozole)


Fulvestrant 500 mg >> 250 mg


Aromatase inhibitors (3rd generation)*


Aromatase inhibitors (3rd generation) (>non-Al)
1. Bonneterre, J, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma Cancer 2001 92
CDK4/6 metaanalysis


CDK4/6 inhibitor management


Letrozole and palbociclib (vs. letrozole alone)


**Fulvestrant 500 mg plus Palbociclib (vs. Fulvestrant alone)**


**Letrozol plus Ribociclib**


**Fulvestrant plus Ribociclib**


**Fulvestrant plus Abemaciclib**


**Non-steroidal AI plus Abemaciclib**


**CDK4/6i metaanalysis**


**CDK4/6i after CDK4/6i**

1. Wander SA, Zangardi M, Niemierko A et a. A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). DOI: 10.1200/JCO.2019.37.15_suppl.1057, JCO 37

**Exemestane and everolimus (vs. exemestane alone)**


**Tamoxifen and everolimus**


**Fulvestrant and everolimus**

1. Kornblum NS, et al. PrECOG 0102: A randomized, double-blind, phase II trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer (MBC) resistant to aromatase
inhibitor (AI) therapy. SABCS 2016,#S1-02

**Letrozole and everolimus**


**Abemaciclib Monotherapy**

Maintenance of bevacizumab plus endocrine therapy


Bevacizumab plus endocrine treatment as first line


Olaparib


Talazoparib


Diagnostik und Therapie früher und fortgeschrittener Mammakarzinome

HER2-positives und HR-positives metastasiertes Mammakarzinom
Anastrozole and trastuzumab


Letrozole and trastuzumab


**Letrozole and lapatinib**


**Fulvestrant and lapatinib**

AI and trastuzumab/pertuzumab


Abemaciclib plus Fulvestrant plus Trastuzumab

Concomitant endocrine-cytotoxic treatment


Maintenance endocrine therapy after chemotherapy induced response
